Page 167 - CW E-Magazine (2-7-2024)

News from Abroad

SAFETY CONCERNS
EU Commission announces new restrictions

on silicones in cosmetics

The European Commission, has However, it is important to note mum concentration of 0.1% in rinse-off
in May, announced an amended in the that D4, which is strongly suspected to and leave-on cosmetic products.
REACH regulation pertaining to octa- have endocrine disrupting effects, has
methylcyclotetrasiloxane (D4), deca- been banned since January 1, 2022 in According to the European Com-
methylcyclopentasiloxane (D5) and cosmetic products. Therefore, the new mission, the new restrictions are nec-
dodecamethylcyclohexasiloxane (D6). REACH restrictions for this substance essary to address the environmental
The amendment imposes stricter limits do not change anything for the cosme- risks associated with the use of these
on the use of these chemicals in wash- tics industry. Likewise, the use of D5 is substances in consumer products. The
off cosmetics and other consumer and already restricted up to a maximum con- Risk Assessment Committee (RAC) of
professional products. centration of 0.1% in rinse-off cosmetic ECHA identifi ed cosmetic products as
products, since January 31, 2020. Fur- the main source of release of D4, D5
The new regulation provides that, thermore, the Commission granted an and D6 that tend to accumulate into the
after 6 June 2026, D4, D5 or D6 shall additional period of one year to the cos- aquatic system and into the atmosphere.
not be placed on the market: as a sub- metics industry to comply with the new
stance on its own; as a constituent of regulation. As a consequence, as of June Due to their broad applications,
other substances; or in mixtures; in a 6, 2027, the use of D5 will be restricted restrictions on D5 in textile, leather, and
concentration equal to or greater than up to a maximum concentration of 0.1% fur dry cleaning, as well as on D4, D5,
0.1 % by weight of the respective in leave-on cosmetic products, and the and D6 in pharmaceuticals and veteri-
substance. use of D6 will be restricted up to a maxi- nary medicines, have been postponed.

Swiss CDMO, Celonic, opens biologics development

centre and pilot plant

The Celonic Group, a Swiss of the Celonic Group,
biologics CDMO (Contract Deve- commented, “The cost
lopment and Manufacturing and complexity of scal-
Organisation) has inaugurated ing a biologic drug
a biologics development centre from the lab bench to
and pilot plant in Basel, Swit- market-scale produc-
zerland. tion poses a significant
barrier to innovation.
This laboratory expansion Celonic’s Biologics
will help pharmaceutical com- Development Centre ex-
panies develop and optimise pansion equipped with
processes using bioprocessing state-of-the-art ‘Next
technologies such as process Generation’ bioprocess-
intensifi cation and perfusion. The ing technologies offers
new centre will work seamlessly capabilities that signi-
with Celonic’s GMP manu- ficantly increase the
facturing site in Heidelberg, amount of active ingre-
Germany. dient produced, reduc-
ing the cost per gram of
Ms. Samanta Cimitan, CEO finished product.”

Chemical Weekly July 2, 2024 167

Contents Index to Advertisers Index to Products Advertised